# Haemonetics Corp: overview

HAE · NYSE · CIK 313143 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Apr 3

Pages: [Overview](/companies/hae.md) · [Financials](/companies/hae/financials.md) · [Filings](/companies/hae/filings.md) · [Insiders](/companies/hae/insiders.md)

Latest reported revenue: [$339.4m](/filings/0000313143-26-000120.md) for Q1 FY2027, three months to 2026-06-27, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000313143-26-000120).

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-09-28) | Q3 FY2025 (2024-12-28) | Q4 FY2025 (2025-03-29) | Q1 FY2026 (2025-06-28) | Q2 FY2026 (2025-09-27) | Q3 FY2026 (2025-12-27) | Q4 FY2026 (2026-03-28) | Q1 FY2027 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [346](/filings/0000313143-25-000075.md) | [349](/filings/0000313143-26-000010.md) | [331 d](/filings/0000313143-26-000050.md) | [321](/filings/0000313143-26-000120.md) | [327](/filings/0000313143-25-000075.md) | [339](/filings/0000313143-26-000010.md) | [346 d](/filings/0000313143-26-000050.md) | [339](/filings/0000313143-26-000120.md) |
| Gross margin | % | [54.2%](/filings/0000313143-25-000075.md) | [55.5%](/filings/0000313143-26-000010.md) | [58.4% d](/filings/0000313143-26-000050.md) | [59.8%](/filings/0000313143-26-000120.md) | [59.5%](/filings/0000313143-25-000075.md) | [59.7%](/filings/0000313143-26-000010.md) | [57.2% d](/filings/0000313143-26-000050.md) | [59.8%](/filings/0000313143-26-000120.md) |
| Operating margin | % | [15.0%](/filings/0000313143-25-000075.md) | [16.9%](/filings/0000313143-26-000010.md) | [21.6% d](/filings/0000313143-26-000050.md) | [16.8%](/filings/0000313143-26-000120.md) | [17.9%](/filings/0000313143-25-000075.md) | [19.9%](/filings/0000313143-26-000010.md) | [(6.6%) d](/filings/0000313143-26-000050.md) | [16.9%](/filings/0000313143-26-000120.md) |
| Net margin | % | [9.8%](/filings/0000313143-26-000010.md) | [10.8%](/filings/0000313143-26-000010.md) | [17.5% d](/filings/0000313143-26-000050.md) | [10.6%](/filings/0000313143-26-000120.md) | [11.8%](/filings/0000313143-26-000010.md) | [13.2%](/filings/0000313143-26-000010.md) | [(5.8%) d](/filings/0000313143-26-000050.md) | [9.7%](/filings/0000313143-26-000120.md) |
| Diluted EPS | $ per share | [0.66](/filings/0000313143-25-000075.md) | [0.74](/filings/0000313143-26-000010.md) | not reported | [0.70](/filings/0000313143-26-000120.md) | [0.81](/filings/0000313143-25-000075.md) | [0.95](/filings/0000313143-26-000010.md) | not reported | [0.72](/filings/0000313143-26-000120.md) |
| Free cash flow | $m | [39.4 d](/filings/0000313143-25-000075.md) | [35.2 d](/filings/0000313143-26-000010.md) | [101 d](/filings/0000313143-26-000050.md) | [13.6](/filings/0000313143-26-000120.md) | [106 d](/filings/0000313143-25-000075.md) | [87.2 d](/filings/0000313143-26-000010.md) | [53.3 d](/filings/0000313143-26-000050.md) | [44.4](/filings/0000313143-26-000120.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-04-02) | FY2023 (2023-04-01) | FY2024 (2024-03-30) | FY2025 (2025-03-29) | FY2026 (2026-03-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [993](/filings/0000313143-24-000020.md) | [1,169](/filings/0000313143-25-000025.md) | [1,309](/filings/0000313143-26-000050.md) | [1,361](/filings/0000313143-26-000050.md) | [1,334](/filings/0000313143-26-000050.md) |
| Gross margin | % | [50.9%](/filings/0000313143-24-000020.md) | [52.6%](/filings/0000313143-25-000025.md) | [52.8%](/filings/0000313143-26-000050.md) | [55.0%](/filings/0000313143-26-000050.md) | [59.0%](/filings/0000313143-26-000050.md) |
| Operating margin | % | [8.1%](/filings/0000313143-24-000020.md) | [13.4%](/filings/0000313143-25-000025.md) | [12.6%](/filings/0000313143-26-000050.md) | [16.3%](/filings/0000313143-26-000050.md) | [11.7%](/filings/0000313143-26-000050.md) |
| Net margin | % | [4.4%](/filings/0000313143-24-000020.md) | [9.9%](/filings/0000313143-25-000025.md) | [9.0%](/filings/0000313143-26-000050.md) | [12.3%](/filings/0000313143-26-000050.md) | [7.3%](/filings/0000313143-26-000050.md) |
| Diluted EPS | $ per share | [0.84](/filings/0000313143-24-000020.md) | [2.24](/filings/0000313143-25-000025.md) | [2.29](/filings/0000313143-26-000050.md) | [3.31](/filings/0000313143-26-000050.md) | [2.05](/filings/0000313143-26-000050.md) |
| Free cash flow | $m | [75.8](/filings/0000313143-24-000020.md) | [81.7](/filings/0000313143-25-000025.md) | [144](/filings/0000313143-26-000050.md) | [142](/filings/0000313143-26-000050.md) | [260](/filings/0000313143-26-000050.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hae/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $443.2m | 5,909,258 |  | Added +289,279 |
| [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $313.5m | 4,179,443 |  | Added +618,525 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $191.0m | 2,546,394 |  | Reduced −12,922 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $165.0m | 2,266,489 |  | Reduced −1,090,054 |
| [ARIEL INVESTMENTS, LLC](/funds/936753.md) | 2026-06-30 | $154.6m | 2,060,966 |  | New +2,060,966 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $154.5m | 2,059,578 |  | Reduced −30,811 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $136.4m | 1,818,186 |  | Added +45,288 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $118.9m | 1,585,222 |  | Added +259,165 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $113.3m | 1,510,120 |  | Added +1,251,967 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $96.6m | 1,287,240 |  | Added +68,262 |

## Recent filings

[All 1,382 filings](/companies/hae/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-08 | 10:15 ET | [8-K](/filings/0000313143-26-000138.md) | 7.01 Regulation FD disclosure | 0000313143-26-000138 |
| 2026-08-18 | 10:03 ET | [8-K](/filings/0000313143-26-000135.md) | 7.01 Regulation FD disclosure | 0000313143-26-000135 |
| 2026-08-06 | 10:09 ET | [10-Q](/filings/0000313143-26-000120.md) | Quarterly report, period 2026-06-27 | 0000313143-26-000120 |
| 2026-08-06 | 10:07 ET | [8-K](/filings/0000313143-26-000118.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000313143-26-000118 |
| 2026-07-28 | 20:28 ET | [8-K](/filings/0000313143-26-000095.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000313143-26-000095 |
| 2026-06-09 | 20:17 ET | [DEF 14A](/filings/0000313143-26-000074.md) | Proxy statement, period 2026-03-28 | 0000313143-26-000074 |
| 2026-06-05 | 10:33 ET | [8-K](/filings/0000313143-26-000057.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000313143-26-000057 |
| 2026-05-20 | 10:31 ET | [10-K](/filings/0000313143-26-000050.md) | Annual report, period 2026-03-28 | 0000313143-26-000050 |
| 2026-05-07 | 10:02 ET | [8-K](/filings/0000313143-26-000031.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000313143-26-000031 |
| 2026-05-01 | 20:18 ET | [8-K](/filings/0000313143-26-000023.md) | 5.02 Departure or appointment of officers or directors | 0000313143-26-000023 |

## Latest annual report

[Form 10-K for the fiscal year ended Mar 28, 2026](/filings/0000313143-26-000050.md), filed May 20, 2026.

## Forecast league

Q2 FY2027, the quarter ended 2026-09-27, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b83d4b1b-d0b6-4363-adab-9b181fbef36c)

## About the filer

- CIK: 313143
- Tickers: HAE
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: MA
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:21 ET. No prices; not investment advice.